Level A· Stronger Clinical EvidenceSystematic ReviewEurope PMCOpen access

Type VIII collagen: advances in matrix biology and translational promise

Shi H., Yu Y., Guo K., He R.

Systematic Review on Chronic Kidney Disease, published in Front Bioeng Biotechnol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Front Bioeng Biotechnol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41641337
PMCID
PMC12864517
DOI
10.3389/fbioe.2025.1732988
Citations
1

Abstract (original English)

Type VIII collagen, a member of the short-chain collagen family, plays essential roles in structural support, functional regulation, and mechanobiology across multiple organ systems. Although early studies suggested ubiquitous expression, emerging single-cell transcriptomic and proteomic analyses have refined this view, demonstrating selective enrichment in corneal endothelial cells, vascular smooth muscle cells, activated fibroblasts, and tumor-associated extracellular matrix (ECM) compartments. These findings establish type VIII collagen as both a structural constituent of the ECM and a dynamic regulator of cell behavior. Functionally, type VIII collagen is critical for endothelial cell stability, angiogenesis, ECM remodeling, and mechanosignaling. Dysregulation of Col8a1 and Col8a2 is implicated in a broad spectrum of disorders, including vascular remodeling, tissue fibrosis, diabetic nephropathy, cancer progression, and corneal endothelial dystrophies. With growing mechanistic insight, translational applications are rapidly expanding. Current directions include gene-editing strategies targeting Col8a2 for Fuchs' endothelial corneal dystrophy, RNA-based approaches to dissect Col8a1 and Col8a2 regulation in fibrotic and vascular disease, and the development of biomaterials incorporating type VIII collagen-derived motifs to promote endothelial repair and guide angiogenesis. Mo

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research